Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
V414106-1mg
|
1mg |
3
|
$207.90
|
|
|
V414106-2mg
|
2mg |
3
|
$345.90
|
|
|
V414106-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$761.90
|
|
|
V414106-10mg
|
10mg |
3
|
$1,236.90
|
|
|
V414106-25mg
|
25mg |
2
|
$2,523.90
|
|
|
V414106-50mg
|
50mg |
2
|
$4,305.90
|
|
Drug-Linker Conjugates for ADC
| Synonyms | 1702967-37-0 | Vipivotide tetraxetan | s8670 | PSMA617 | PSMA-617 | Sodium phosphate monobasic monohydrate, BioXtra, for molecular biology, >=99.5% (T) | NACLO3 | -LYSINE, N2-((((1S)-1,3-DICARBOXYPROPYL)AMINO)CARBONYL)-N6-(3-(2-NAPHTHALENYL)-N-((TRANS-4-( |
|---|---|
| Specifications & Purity | Moligand™, ≥98% |
| Biochemical and Physiological Mechanisms | Vipivotide tetraxetan (PSMA-617) is a chemically modified PSMA(prostate-specific membrane antigen) inhibitor with a Ki of 0.37 nM. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Grade | Moligand™ |
| Action Type | INHIBITOR |
| Mechanism of action | Inhibitor of Folate hydrolase (prostate-specific membrane antigen) 1 |
| Product Description |
Information Vipivotide tetraxetan (PSMA-617) is a chemically modified PSMA(prostate-specific membrane antigen) inhibitor with a Ki of 0.37 nM. Targets PSMA (Cell-free assay) 0.37 nM(Ki) In vitro PSMA-617 demonstrates high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant Ki = 2.34 ± 2.94 nM on LNCaP; Ki = 0.37 ± 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells are demonstrated. In vivo The small-animal PET measurements show high tumor-to-background contrasts as early as 1 h after injection. In vivo distribution reveals specific uptake in LNCaP tumors and in the kidneys 1 h after injection. With regard to therapeutic use, PSMA-617 exhibits a rapid clearance from the kidneys from 113.3 ± 24.4 at 1 h to 2.13 ± 1.36 percentage injected dose per gram at 24 h. The favorable pharmacokinetics of the molecule leads to tumor-to-background ratios of 1,058 (tumor to blood) and 529 (tumor to muscle), respectively,24 h after injection. Cell Research(from reference) Cell lines:PSMA-positive LNCaP cell line Concentrations:0–5000 nM Incubation Time:1 h |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Hexacarboxylic acids and derivatives |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Hexacarboxylic acids and derivatives |
| Alternative Parents | Glutamic acid and derivatives N-carbamoyl-alpha amino acids N-acyl-alpha amino acids and derivatives Alpha amino acid amides Naphthalenes Alpha amino acids N-acyl amines Trialkylamines Organic carbonic acids and derivatives Amino acids Carboxylic acids Carboxylic acid amides Azacyclic compounds Organopnictogen compounds Organooxygen compounds Organic oxides Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Hexacarboxylic acid or derivatives - Glutamic acid or derivatives - N-carbamoyl-alpha-amino acid or derivatives - N-carbamoyl-alpha-amino acid - N-acyl-alpha amino acid or derivatives - Alpha-amino acid amide - Naphthalene - Alpha-amino acid or derivatives - N-substituted-alpha-amino acid - Alpha-amino acid - Fatty acyl - Benzenoid - N-acyl-amine - Fatty amide - Amino acid - Tertiary aliphatic amine - Tertiary amine - Carbonic acid derivative - Carboxamide group - Amino acid or derivatives - Azacycle - Organoheterocyclic compound - Carboxylic acid - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Amine - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as hexacarboxylic acids and derivatives. These are carboxylic acids containing exactly six carboxyl groups. |
| External Descriptors | Not available |
|
|
|
| ALogP | -11.549 |
|---|---|
| HBD Count | 5 |
| Rotatable Bond | 27 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Pubchem Sid | 504772988 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504772988 |
| IUPAC Name | (2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid |
| INCHI | InChI=1S/C49H71N9O16/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74)/t32?,35?,37-,38-,39-/m0/s1 |
| InChIKey | JBHPLHATEXGMQR-VLOIPPKDSA-N |
| Smiles | C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O |
| Isomeric SMILES | C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O |
| PubChem CID | 122706786 |
| Molecular Weight | 1042.14 |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Aug 16, 2022 | V414106 | |
| Certificate of Analysis | Aug 16, 2022 | V414106 | |
| Certificate of Analysis | Aug 16, 2022 | V414106 | |
| Certificate of Analysis | Aug 16, 2022 | V414106 | |
| Certificate of Analysis | Aug 16, 2022 | V414106 |
| Solubility | Solubility (25°C) In vitro Water: 100 mg/mL (95.95 mM); |
|---|---|
| DMSO(mg / mL) Max Solubility | -1 |
| DMSO(mM) Max Solubility | -0.959563974130155 |
| Water(mg / mL) Max Solubility | 100 |
| Water(mM) Max Solubility | 95.9563974130155 |
| Molecular Weight | 1042.099 g/mol |
| XLogP3 | -8.200 |
| Hydrogen Bond Donor Count | 11 |
| Hydrogen Bond Acceptor Count | 20 |
| Rotatable Bond Count | 27 |
| Exact Mass | 1041.5 Da |
| Monoisotopic Mass | 1041.5 Da |
| Topological Polar Surface Area | 365.000 Ų |
| Heavy Atom Count | 74 |
| Formal Charge | 0 |
| Complexity | 1870.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |